Semaglutide, a GLP-1 receptor agonist originally approved for diabetes management under the name Ozempic, has shown promising results in aiding weight loss. Clinical trials have demonstrated that semaglutide can lead to substantial weight loss, with participants losing up to 15% of their body weight.
Recently, a similar drug, Wegovy, received FDA approval specifically for weight loss. However, due to a significant drug shortage, many are turning to Ozempic as an alternative. This brings up an important concern regarding the safety of Ozempic for weight loss in non-diabetics.
In this article, we explore the increasing use of Ozempic for weight loss, providing insights from medical professionals on its effectiveness, safety, and the essential factors to consider before using Ozempic for weight management.
How Does Ozempic Work for Weight Loss?
Ozempic contains the active ingredient semaglutide, which belongs to the class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
The mechanism of action of semaglutide involves mimicking the action of the hormone GLP-1 in the body. GLP-1 is naturally produced in the intestines in response to food intake and helps regulate blood sugar levels by stimulating insulin release, reducing glucagon secretion (which lowers blood sugar), slowing gastric emptying, and promoting satiety (feeling of fullness).
By acting as a GLP-1 receptor agonist, Ozempic improves blood sugar control and reduces appetite, leading to potential weight loss. Based on clinical trials, here’s how much weight one can expect to lose on Ozempic:
- SUSTAIN 1: This global trial compared semaglutide once-weekly to placebo in type 2 diabetes patients who had never used medications before. Over 30 weeks, those on 0.5 mg and 1.0 mg lost 8.23 lbs and 9.99 lbs, respectively, while those on placebo lost 2.16 lbs.
- SUSTAIN 2: In a 56-week trial, patients on weekly injectable semaglutide saw greater weight reductions compared to daily oral sitagliptin. Semaglutide 0.5 mg and 1.0 mg led to reductions of 9.48 lbs and 13.45 lbs, respectively, while sitagliptin users experienced an average reduction of 4.19 lbs.
- SUSTAIN 3: In this trial, subjects with type 2 diabetes taking oral antidiabetic drugs were randomly assigned to either semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks. Mean body weight (211.2 lbs at baseline) decreased by 12.35 lbs with semaglutide and 4.19 lbs with exenatide ER.
- SUSTAIN 4: This trial evaluated the efficacy and safety of semaglutide versus insulin glargine in patients with type 2 diabetes insufficiently controlled with metformin (with or without sulfonylureas). At week 30, semaglutide at doses of 0.5 mg and 1.0 mg resulted in weight reductions of 7.65 lbs and 11.39 lbs, respectively, while patients on insulin glargine experienced a weight gain of 2.54 lbs.
- SUSTAIN 5: This trial assessed the efficacy and safety of semaglutide as an add-on to basal insulin. Mean body weight decreased with semaglutide 0.5 and 1.0 mg vs. placebo from baseline to end of treatment by 8.16 lbs, 14.11 lbs, and 3.09 lbs, respectively.
What is the Dose of Ozempic for Weight Loss?
Since Ozempic is not officially approved for weight loss, there is no specific dose dedicated for this purpose. However, when used for its primary indication of treating type 2 diabetes, the typical dosing regimen is as follows:
| Medication | Starting Dose | Titration Dose | Maximum Dose | ||||
| Month 1 | Month 2 | Month 3 | Month 4 | Month 5+ | |||
| Ozempic | 0.25 mg once weekly | 0.25 mg per week | 0.5 mg per week | 0.5-1.0 mg per week | 1.0-2.0 mg per week | 1.0-2.0 mg per week | 2.0 mg once weekly |
The adjustments depend on the individual’s response and tolerability, meaning that the dosage may be increased or decreased based on how well the person is managing the medication and any side effects they may be experiencing. Individual factors such as age, weight, medical history, and concurrent medications can also influence how adjustments are made to the Ozempic dosage.
What are the Side Effects of Ozempic for Weight Loss?
Using Ozempic for weight loss does not result in any side effects that differ from its use for diabetes management. In fact, weight loss itself is a known side effect of Ozempic when used for its primary indication of treating type 2 diabetes. The common side effects of Ozempic include:
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Constipation
Other side effects include:
- Hypoglycemia
- Injection site reactions
- Increases in amylase and lipase
- Cholelithiasis
- Increased heart rate
- Fatigue, dysgeusia, and dizziness
- Other gastrointestinal adverse reactions (dyspepsia, eructation, flatulence, gastroesophageal reflux disease, and gastritis)
Ozempic may also have potential risks or safety concerns that users need to be aware of, such as:
- Pancreatitis
- Diabetic Retinopathy
- Acute Kidney Injury
- Risk of Thyroid C-Cell Tumors
- Hypersensitivity
Can Ozempic Be Prescribed for Weight Loss?
Healthcare providers may prescribe Ozempic off-label for weight loss based on clinical judgment and the patient’s individual health needs. While Ozempic can help with weight loss, it should only be used under the guidance of a healthcare professional who can monitor its effects and adjust the dosage as necessary.
Who Qualifies for Ozempic for Weight Loss?
The eligibility criteria for being prescribed Ozempic off-label for weight loss typically include several factors to ensure suitability and safety. These may include:
- Body Mass Index (BMI): A BMI of 30 or higher (classified as obesity) or a BMI of 27 or higher with at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia.
- Medical History: A thorough evaluation of the patient’s medical history to rule out any contraindications or potential risks associated with semaglutide. This includes assessing for any history of pancreatitis, thyroid cancer, or other significant health conditions.
- Previous Weight Loss Efforts: Documentation of previous attempts to lose weight through diet, exercise, and other lifestyle modifications. Healthcare providers may consider prescribing Ozempic off-label if these efforts have not resulted in significant or sustained weight loss.
- Commitment to Lifestyle Changes: A willingness to adhere to a comprehensive weight management program, including dietary changes, increased physical activity, and regular follow-up appointments with the healthcare provider.
- Age: Adults over 18 may typically be considered for off-label use. Pediatric use is generally not recommended unless under specific circumstances and specialist guidance.
- Risk Assessment: An overall assessment of the risks and benefits of using Ozempic for weight loss in the patient’s specific context, ensuring that the potential benefits outweigh the risks.
Patients must have a detailed discussion with their healthcare provider to determine if the off-label use of Ozempic is appropriate for their situation.
Is Ozempic Safe for Non-Diabetics?
Ozempic has not been specifically tested for weight loss in non-diabetics. However, higher doses of its active ingredient, semaglutide, have been shown to be safe and effective for weight loss in people without diabetes.
Additionally, using Ozempic for weight loss can provide significant benefits for individuals struggling with obesity. Weight loss can improve overall health, reduce the risk of chronic diseases, and enhance quality of life. Specific advantages of weight loss include:
- Improved Metabolic Health: Weight loss can improve metabolic parameters such as blood pressure, cholesterol levels, and insulin sensitivity, reducing the risk of metabolic syndrome and other obesity-related conditions.
- Reduced Risk of Chronic Diseases: Weight loss can help lower the risk of developing chronic diseases associated with obesity, including heart disease, stroke, type 2 diabetes, and certain types of cancer.
- Enhanced Quality of Life: Significant weight loss can lead to improvements in physical mobility, energy levels, and overall quality of life. Many individuals also experience better mental health and self-esteem as a result of weight loss.
- Decreased Joint Pain: Obesity increases the mechanical load on weight-bearing joints, particularly the knees, hips, and lower back, accelerating wear and tear. This extra pressure can cause cartilage breakdown, inflammation, and pain, severely impacting mobility and quality of life. Weight loss can alleviate this strain, reducing joint pain and slowing the progression of osteoarthritis.
- Lowered Inflammation: Obesity is linked to chronic inflammation, which can cause various health issues. Excess fat, especially visceral fat, releases pro-inflammatory cytokines, leading to low-grade inflammation. This increases the risk of cardiovascular disease, type 2 diabetes, and certain cancers. Reducing inflammation improves overall health and lowers the risk of these conditions, leading to better long-term health outcomes.
The benefits of weight loss with Ozempic may outweigh the risks associated with obesity, leading to significant improvements in health and quality of life.
Off-Label Use: Ethical and Regulatory Considerations
Off-label drug use refers to prescribing medications for purposes not officially approved by the FDA. This can include treating different diseases, using the drug in unapproved dosages or forms, or administering it to unapproved patient groups (e.g., children or pregnant women). Although the FDA regulates which medications can be marketed and their approved uses, it does not control how doctors prescribe them once they are available.
Reasons for off-label drug use:
- Lack of Studies: Many medications haven’t been specifically studied for all populations (e.g., pediatric, geriatric).
- Urgent Medical Needs: In life-threatening situations, doctors may use any available and logical treatment, regardless of FDA approval.
- Drug Classes: If one drug in a class is FDA-approved for a condition, doctors might use other drugs in the same class similarly.
- Similar Conditions: Medications approved for one condition may be used for another if the conditions share pathologic or physiologic features (e.g., using a drug for both diabetes and metabolic syndrome).
Off-label drug use is quite common. For instance, a 2006 study found that 21% of prescriptions for commonly used medications were off-label. In pediatric hospitals, 78.9% of children were discharged with at least one off-label medication. Off-label use is also prevalent in intensive care units, psychiatry, and headache specialty practices.
One of the major hurdles of off-label use is the financial burden. Insurance companies are less likely to cover medications prescribed off-label, making Ozempic an expensive option for weight loss. Costs can range from several hundred to over a thousand dollars per month, which may not be feasible for many patients.
Lastly, the rising popularity of Ozempic for weight loss may impact diabetic patients who need the medication for blood sugar control. This raises ethical questions about resource allocation and the prioritization of medication availability.
Helpful Article:
If you’re curious about whether your insurance can cover Ozempic, we have a comprehensive guide available. This guide includes detailed information about the criteria or formulary from well-known insurance providers such as BCBS, Aetna, and Humana. To find out more, check out our guide here [Is Ozempic Covered by Insurance?].
Alternatives to Ozempic for Weight Loss
For those seeking medications specifically indicated for weight loss, here are some substitutes for Ozempic:
1. Wegovy (semaglutide)
Wegovy belongs to the same class of medications as Ozempic. However, Wegovy is administered at a higher dose of up to 2.4 mg once weekly. In a 68-week trial, those on Wegovy lost an average of 37.04 lbs, while the placebo group lost 13.67 lbs.
As with any medication, Wegovy can cause side effects. Common side effects include discomfort in the abdomen, vomiting, nausea, diarrhea, constipation, and headaches. These side effects are similar to those reported with Ozempic. However, due to its higher dosage, Wegovy may lead to a higher incidence of gastrointestinal side effects than Ozempic.
2. Saxenda (liraglutide)
Saxenda is another FDA-approved drug with a similar indication to Wegovy. However, it contains a different active ingredient called liraglutide. Despite this difference, Saxenda belongs to the same drug class as Wegovy and Ozempic, known as GLP-1 agonists.
The first major phase 3 trial of liraglutide, which lasted 20 weeks, resulted in significantly greater weight loss than placebo (approximately 6.2 lbs), with reductions ranging from approximately 10.6 lbs to 15.8 lbs.
Saxenda shares similar side effects with other GLP-1 receptor agonists, including nausea, diarrhea, constipation, vomiting, and abdominal pain.
3. Zepbound (tirzepatide)
Zepbound is a relatively new medication for weight management. Average weight loss during clinical trials of Zepbound ranged from 34 to 48 lbs for non-diabetic adults and from 28 to 33 lbs for adults with diabetes.
Due to its dual GLP-1 and GIP agonist action, Zepbound may induce more side effects than Wegovy and Saxenda. Reported side effects during clinical trials, occurring in more than 5% of patients treated with Zepbound, include nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease.
Helpful Article:
If you’re interested in exploring alternatives to Ozempic, including cheap alternatives and natural alternatives, we have an article that covers the top options available. This comprehensive guide provides detailed insights and comparisons to help you find the best fit for your needs. You can find this informative article here.
How to Get Prescribed Ozempic for Weight Loss
Seeking a prescription for Ozempic for weight loss involves a thorough and well-informed process. Here are some steps to guide you through the conversation:
- Understand the Off-Label Use: Make sure to discuss the fact that using Ozempic for weight loss is an off-label use. Ask about the implications of this and any additional considerations your doctor might have. Write down specific questions about using Ozempic for weight loss, including its benefits, risks, side effects, and how it compares to other weight loss treatments. Here are some important questions to consider asking your healthcare provider:
-
- What is this medication officially approved to treat?
- Are there other approved medications or therapies for my condition?
- What scientific evidence supports the use of this medication for my condition?
- Is this medication likely to be more effective than existing approved treatments for my condition?
- What are the potential benefits and risks of using this medication for my condition?
- Will my health insurance cover the use of this medication for my condition?
- Are there any clinical trials available that involve this medication for my condition that I could join?
- Discuss Your Medical History: Provide your doctor with a comprehensive overview of your medical history, including any previous weight loss efforts, current medications, and any underlying health conditions. This information is crucial for your doctor to assess whether Ozempic is a suitable option for you.
- Express Your Goals: Clearly articulate your weight loss goals and why you are considering Ozempic. Explain any difficulties you have faced with other weight loss methods and how you believe Ozempic might help.
- Ask About Monitoring: Inquire about the necessary monitoring and follow-up appointments required while using Ozempic. Understanding the process will help you stay informed and adhere to your treatment plan.
By being well-prepared and open in your discussion, you can work with your doctor to determine if Ozempic is the right choice for your weight loss journey.
Bottom Line
Using Ozempic for weight loss shows promising results, leveraging its ability to regulate metabolism and control appetite. Although it is primarily approved for treating type 2 diabetes, clinical studies on higher doses of semaglutide indicate it can be safe and effective for weight management.
This off-label use can provide significant health benefits, such as improved metabolic health and reduced risk of chronic diseases. However, discussing this option with a healthcare provider is crucial to ensure it aligns with individual health needs and to understand the potential risks and benefits. While Ozempic can be an effective weight loss tool for non-diabetics, off-label use requires careful consideration of efficacy, safety, cost, and ethical implications.
Frequently Asked Questions
Related Articles
Sources
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., Lingvay, I., & STEP 2 Study Group (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London, England), 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
Sorli, C., Harashima, S. I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The lancet. Diabetes & endocrinology, 5(4), 251–260. https://doi.org/10.1016/S2213-8587(17)30013-X
Ahrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017). Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. The lancet. Diabetes & endocrinology, 5(5), 341–354. https://doi.org/10.1016/S2213-8587(17)30092-X
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018). Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes care, 41(2), 258–266. https://doi.org/10.2337/dc17-0417
Aroda, V. R., Bain, S. C., Cariou, B., Pileti?, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017). Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. The lancet. Diabetes & endocrinology, 5(5), 355–366. https://doi.org/10.1016/S2213-8587(17)30085-2
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P. L., Wijayasinghe, N., & Norwood, P. (2018). Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. The Journal of clinical endocrinology and metabolism, 103(6), 2291–2301. https://doi.org/10.1210/jc.2018-00070
Khanna, D., Khanna, S., Khanna, P., Kahar, P., & Patel, B. M. (2022). Obesity: a chronic Low-Grade inflammation and its markers. https://doi.org/10.7759/cureus.22711
Radley, D. C., Finkelstein, S. N., & Stafford, R. S. (2006). Off-label prescribing among office-based physicians. Archives of internal medicine, 166(9), 1021–1026. https://doi.org/10.1001/archinte.166.9.1021
Wittich, C. M., Burkle, C. M., & Lanier, W. L. (2012). Ten common questions (and their answers) about off-label drug use. Mayo Clinic Proceedings, 87(10), 982–990. https://doi.org/10.1016/j.mayocp.2012.04.017
Shah, S. S., Hall, M., Goodman, D. M., Feuer, P., Sharma, V., Fargason, C., Jr, Hyman, D., Jenkins, K., White, M. L., Levy, F. H., Levin, J. E., Bertoch, D., & Slonim, A. D. (2007). Off-label drug use in hospitalized children. Archives of pediatrics & adolescent medicine, 161(3), 282–290. https://doi.org/10.1001/archpedi.161.3.282
